Physician profile
Jack R Lichtenstein
NPI 1609844224
$13,805.22
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,927 · 2020: $2,961 · 2021: $2,850 · 2022: $4,036 · 2023: $30.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $30.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $30.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,335.67 | 2019-2022 | |
| Amgen INC. | $2,274.95 | 2019-2022 | |
| Abbvie INC. | $1,669.57 | 2019-2022 | |
| Janssen Biotech, INC. | $905.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $855.79 | 2019-2022 | |
| Ucb, INC. | $764.35 | 2019-2022 | |
| Lilly USA, LLC | $756.83 | 2019-2022 | |
| Horizon Therapeutics Plc | $628.32 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $580.66 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $355.62 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $347.13 | 2019 | |
| Aurinia Pharma U.S., INC. | $267.63 | 2021-2022 | |
| Antares Pharma, INC. | $258.94 | 2019-2021 | |
| Radius Health, INC. | $222.74 | 2019-2022 | |
| Genentech USA, INC. | $162.52 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $151.44 | 2019-2022 | |
| Celgene Corporation | $150.78 | 2019 | |
| Glaxosmithkline, LLC. | $149.16 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $139.08 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $118.58 | 2019 | |
| Sobi, INC | $112.41 | 2019-2020 | |
| Bio Products Laboratory USA, INC. | $100.04 | 2020-2023 | Coagadex, Gammaplex |
| Pacira Therapeutics, INC. | $93.55 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.60 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $52.39 | 2019-2021 | |
| Depuy Synthes Sales INC. | $39.38 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $39.37 | 2020-2021 | |
| Allergan, INC. | $38.85 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $38.22 | 2022 | |
| Biodelivery Sciences International, INC. | $22.56 | 2020-2021 | |
| Oxford Immunotec USA INC | $20.83 | 2020 | |
| Eisai INC. | $19.39 | 2020 | |
| Merck Sharp & Dohme LLC | $14.87 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.71 | 2021 | |
| Medexus Pharma, INC. | $11.61 | 2020 | |
| Zimmer Biomet Holdings, INC. | $11.25 | 2019 | |
| Organon LLC | $9.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Lichtenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.